MedTrace Logo

Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.

NCT00150813 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2018-11-21

Study results available
· View outcomes & findings →

Summary

An open-label follow-up trial assessing the long term safety of levetiracetam as per adverse events reporting.

Conditions

  • Epilepsy, Tonic-clonic

Interventions

DRUG

Levetiracetam

Pharmaceutical form: oral tablets Route of administration: Oral use

Sponsors & Collaborators

  • UCB Pharma SA

    lead INDUSTRY

Principal Investigators

  • UCB Cares · 001 844 599 2273 (UCB)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-10
Primary Completion
2007-05-29
Completion
2007-05-29

Countries

  • Czechia
  • Hungary
  • Poland
  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00150813 on ClinicalTrials.gov